

Poly Medicure Limited

Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110 020 (INDIA)
T: +91-11- 33550700, 47317000
E: info@polymedicure.com W: polymedicure.com
CIN: L 40300DL1995PLC066923



Date: 01st June, 2026

Scrip Code: - 531768

Scrip Code:- POLYMED

The Manager,
BSE Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Appointment of Senior Management Personnel (SMP)

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company by way of circular resolutions passed on June 01, 2026 has approved the appointment and remuneration of the below mentioned person as Senior Management Personnel (SMP) of the Company: -

Appointment of Mr. Indranil Mukherjee as Chief Executive Officer - Asia Pacific and India Business, Senior Management Personnel with effect from June 1, 2026.

Further it is informed that Mr. Indranil Mukherjee will report directly to the Managing Director of the Company and accordingly has been categorized as a Senior Management Personnel (SMP) under the SEBI Listing Regulations.

The details required under the SEBI Listing Regulations and SEBI Master Circular bearing No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is attached herewith as **Annexure - A.**

Kindly take note of the same for your further needful and oblige us.

Thanking You,
Yours Sincerely

For Poly Medicure Limited

Avinash Chandra
Company Secretary
M. No. A32270



Annexure - A

DISCLOSURE AS PER LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/PoD2/CIR/P/0155 DATED NOVEMBER 11, 2024

Sr. No.	Particulars	Details
1.	Name of SMP	Mr. Indranil Mukherjee
2.	Reason for change viz., appointment, resignation, removal, death or otherwise	Mr. Indranil Mukherjee appointed as Chief Executive Officer - Asia Pacific and India Business, Senior Management Personnel.
3.	Date of appointment / cessation (as applicable) & term of appointment	Date of Appointment: June 01, 2026. Term of Appointment: Full-Time Employment
4.	Brief profile (in case of appointment)	Mr. Indranil Mukherjee is a seasoned medical technology executive with over 30 years of broad-based leadership experience spanning critical care, infusion therapy, renal care, surgical instruments, vascular systems, wound care, and implantable devices. He has demonstrated track record of acting as a change agent, scaling up business and leading market expansion, M&A and integration, organisational restructuring, and strategy execution. He combines deep industry insight with data-driven decision making to deliver sustainable business outcomes. He built the foundational years of his career at B. Braun, where he managed the company's Hospital Care, Outpatient Market, and Aesculap (Vascular) portfolios across India, before being transferred to B. Braun's headquarters in Germany as Global Sales Manager in 2010, and subsequently serving as Regional Head for Hospital Care at the Asia Pacific headquarters in Penang, Malaysia. In his role as Managing Director at B. Braun Group in India, he delivered a turnaround and sustained profitable growth across multiple product lines spanning three manufacturing plants and a team of over 2,000 colleagues. He later served as Group Chief Executive Officer of Translumina Therapeutics a global cardiovascular implants company with



		<p>operations in India and Germany.</p> <p>His career reflects deep expertise across the full spectrum of medical devices – from medical consumables and infusion products to capital equipment, surgical instruments, and implants and renal service clinics – combined with a proven track record of building high-performance commercial organisations, driving market development, and leading P&L responsibilities at country, regional, and global levels.</p> <p>He graduated in Chemistry from St. Xavier’s College Ranchi and MBA from Bhopal University, followed by SMP from IIM Calcutta and LBTA from INSEAD Singapore.</p>
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

